Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy.
Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces a big challenge due to heterogeneity of tumor, and therapeutic response is complicated by possible immune-related adverse events (irAEs). Therefore, it is critical t...
| Publicado en: | European Journal of Nuclear Medicine & Molecular Imaging Vol. 50; no. 6; pp. 1671 - 1689 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
May2023
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=163230969&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 163230969 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 16197070 NPC jtl: European Journal of Nuclear Medicine & Molecular Imaging issn: 16197070 maglogo: N pubinfo: dt: May2023 vid: 50 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 163230969 161205992 10.1007/s00259-022-06084-1 163230969 ppf: 1671 ppct: 18 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. aug: au: Xing, Xiaoqing Zhao, Qing Zhou, Jinyun Zhou, Rui Liu, Yu Qin, Xiyi Zhang, Mingrong Zhong, Yan Wang, Jing Tian, Mei Zhang, Hong affil: Department of Nuclear Medicine and PET Center, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, 310009, Hangzhou, Zhejiang, China sug: ab: Immune checkpoint inhibitors (ICIs) achieve a milestone in cancer treatment. Despite the great success of ICI, ICI therapy still faces a big challenge due to heterogeneity of tumor, and therapeutic response is complicated by possible immune-related adverse events (irAEs). Therefore, it is critical to assess the systemic immune response elicited by ICI therapy to guide subsequent treatment regimens. Positron emission tomography (PET) molecular imaging is an optimal approach in cancer diagnosis, treatment effect evaluation, follow-up, and prognosis prediction. PET imaging can monitor metabolic changes of immunocytes and specifically identify immuno-biomarkers to reflect systemic immune responses. Here, we briefly review the application of PET molecular imaging to date of systemic immune responses following ICI therapy and the associated rationale. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|